BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Walker LC, Lawrence AJ. The Role of Orexins/Hypocretins in Alcohol Use and Abuse. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 221-46. [DOI: 10.1007/7854_2016_55] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 James MH, Campbell EJ, Dayas CV. Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders. Curr Top Behav Neurosci 2017;33:197-219. [PMID: 28083790 DOI: 10.1007/7854_2016_56] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
2 Campbell EJ, Marchant NJ, Lawrence AJ. A sleeping giant: Suvorexant for the treatment of alcohol use disorder? Brain Res 2020;1731:145902. [PMID: 30081035 DOI: 10.1016/j.brainres.2018.08.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
3 Pallarés V, Dudek M, Moreno A, Pérez-Ramírez Ú, Moratal D, Haaranen M, Ciccocioppo R, Sommer WH, Canals S, Hyytiä P. Neuroimaging reveals functionally distinct neuronal networks associated with high-level alcohol consumption in two genetic rat models. Behav Pharmacol 2021;32:229-38. [PMID: 32925226 DOI: 10.1097/FBP.0000000000000582] [Reference Citation Analysis]
4 Asadi S, Roohbakhsh A, Shamsizadeh A, Fereidoni M, Kordijaz E, Moghimi A. The effect of intracerebroventricular administration of orexin receptor type 2 antagonist on pentylenetetrazol-induced kindled seizures and anxiety in rats. BMC Neurosci 2018;19:49. [PMID: 30103703 DOI: 10.1186/s12868-018-0445-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
5 Ponté C, Giron A, Crequy M, Lapeyre-Mestre M, Fabre N, Salles J. Cluster Headache in Subjects With Substance Use Disorder: A Case Series and a Review of the Literature. Headache 2019;59:576-89. [PMID: 30957220 DOI: 10.1111/head.13516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Choudhary AG, Somalwar AR, Sagarkar S, Rale A, Sakharkar A, Subhedar NK, Kokare DM. CART neurons in the lateral hypothalamus communicate with the nucleus accumbens shell via glutamatergic neurons in paraventricular thalamic nucleus to modulate reward behavior. Brain Struct Funct 2018;223:1313-28. [PMID: 29116427 DOI: 10.1007/s00429-017-1544-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
7 Chieffi S, Carotenuto M, Monda V, Valenzano A, Villano I, Precenzano F, Tafuri D, Salerno M, Filippi N, Nuccio F, Ruberto M, De Luca V, Cipolloni L, Cibelli G, Mollica MP, Iacono D, Nigro E, Monda M, Messina G, Messina A. Orexin System: The Key for a Healthy Life. Front Physiol 2017;8:357. [PMID: 28620314 DOI: 10.3389/fphys.2017.00357] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 13.6] [Reference Citation Analysis]
8 James MH, Bowrey HE, Stopper CM, Aston-Jones G. Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin-1 receptor antagonist in rats. Eur J Neurosci 2019;50:2602-12. [PMID: 30240516 DOI: 10.1111/ejn.14166] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
9 Moorman DE. The hypocretin/orexin system as a target for excessive motivation in alcohol use disorders. Psychopharmacology (Berl) 2018;235:1663-80. [PMID: 29508004 DOI: 10.1007/s00213-018-4871-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
10 Perry CJ, Lawrence AJ. An imperfect model is still useful. Addiction 2020;115:14-6. [PMID: 31496025 DOI: 10.1111/add.14790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 McGinn MA, Pantazis CB, Tunstall BJ, Marchette RCN, Carlson ER, Said N, Koob GF, Vendruscolo LF. Drug addiction co-morbidity with alcohol: Neurobiological insights. Int Rev Neurobiol 2021;157:409-72. [PMID: 33648675 DOI: 10.1016/bs.irn.2020.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Holmes A. Sex and Orexins: Uncovering a Mechanism Underlying Sex Differences in Stress Susceptibility. Biol Psychiatry 2017;81:642-4. [PMID: 28317548 DOI: 10.1016/j.biopsych.2017.02.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Walker LC. A balancing act: the role of pro- and anti-stress peptides within the central amygdala in anxiety and alcohol use disorders. J Neurochem 2021;157:1615-43. [PMID: 33450069 DOI: 10.1111/jnc.15301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 James MH, Mahler SV, Moorman DE, Aston-Jones G. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now? Curr Top Behav Neurosci 2017;33:247-81. [PMID: 28012090 DOI: 10.1007/7854_2016_57] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 16.0] [Reference Citation Analysis]
15 Dong XY, Feng Z. Wake-promoting effects of vagus nerve stimulation after traumatic brain injury: upregulation of orexin-A and orexin receptor type 1 expression in the prefrontal cortex. Neural Regen Res 2018;13:244-51. [PMID: 29557373 DOI: 10.4103/1673-5374.226395] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
16 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
17 James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G. Increased Number and Activity of a Lateral Subpopulation of Hypothalamic Orexin/Hypocretin Neurons Underlies the Expression of an Addicted State in Rats. Biol Psychiatry 2019;85:925-35. [PMID: 30219208 DOI: 10.1016/j.biopsych.2018.07.022] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 11.8] [Reference Citation Analysis]
18 Anderson RI, Moorman DE, Becker HC. Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol. Handb Exp Pharmacol 2018;248:473-503. [PMID: 29526023 DOI: 10.1007/164_2018_100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
19 Mohammadkhani A, James MH, Pantazis CB, Aston-Jones G. Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil. Brain Res 2020;1731:146461. [PMID: 31526801 DOI: 10.1016/j.brainres.2019.146461] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
20 James MH, Fragale JE, O'Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology 2021;183:108359. [PMID: 33091458 DOI: 10.1016/j.neuropharm.2020.108359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Suchting R, Yoon JH, Miguel GGS, Green CE, Weaver MF, Vincent JN, Fries GR, Schmitz JM, Lane SD. Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder. Brain Res 2020;1731:146359. [PMID: 31374218 DOI: 10.1016/j.brainres.2019.146359] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hopf FW. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors. Neuropharmacology 2020;168:108013. [PMID: 32092435 DOI: 10.1016/j.neuropharm.2020.108013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
23 Morley KC, Perry CJ, Watt J, Hurzeler T, Leggio L, Lawrence AJ, Haber P. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opin Pharmacother 2021;22:1291-303. [PMID: 33615945 DOI: 10.1080/14656566.2021.1892641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]